Cargando…
减低剂量环磷酰胺的预处理方案对重型再生障碍性贫血同胞全相合外周血造血干细胞移植疗效的影响
OBJECTIVE: To respectively analyze the impact of conditioning regimens with a dose-decreased cyclophosphamide (Cy) on the outcome in fully matched sibling donor (MSD) peripheral blood stem cell transplantation (PBSCT) for severe aplastic anemia (SAA). METHODS: Two conditioning regimens with differen...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348241/ https://www.ncbi.nlm.nih.gov/pubmed/28954343 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.08.003 |
_version_ | 1783556759851368448 |
---|---|
collection | PubMed |
description | OBJECTIVE: To respectively analyze the impact of conditioning regimens with a dose-decreased cyclophosphamide (Cy) on the outcome in fully matched sibling donor (MSD) peripheral blood stem cell transplantation (PBSCT) for severe aplastic anemia (SAA). METHODS: Two conditioning regimens with different doses of Cy (150 mg/kg or 120 mg/kg) in combination with fludarabine (Flu) and antithymocyte globulin (ATG) for MSD-PBSCT were investigated in 51 patients with acquired SAA. RESULTS: Overall survival and failure-free survival in patients received 150 mg/kg of Cy (Cy150 cohort) or 120 mg/kg (Cy120 cohort) were 93.5% vs 90.0% (χ(2)=0.170, P=0.680) and 90.3% vs 85.0% (χ(2)=0.285, P= 0.594) respectively. However, either acute or chronic graft-versus-host disease risks were higher in Cy120 cohort than in Cy150 cohort (HR=3.89, 95% CI 1.21–12.53, P=0.023; HR=4.48, 95% CI 1.40–14.32, P= 0.011, respectively). No difference was found for opportunistic infections or graft failure between two cohorts. CONCLUSION: Cy at a dose of 150 mg/kg, in combination with Flu and ATG, was more effective than that of 120 mg/kg Cy to produce improved clinical outcome in the setting of acquired SAA patients after MSD-PBSCT. |
format | Online Article Text |
id | pubmed-7348241 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Editorial office of Chinese Journal of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73482412020-07-16 减低剂量环磷酰胺的预处理方案对重型再生障碍性贫血同胞全相合外周血造血干细胞移植疗效的影响 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To respectively analyze the impact of conditioning regimens with a dose-decreased cyclophosphamide (Cy) on the outcome in fully matched sibling donor (MSD) peripheral blood stem cell transplantation (PBSCT) for severe aplastic anemia (SAA). METHODS: Two conditioning regimens with different doses of Cy (150 mg/kg or 120 mg/kg) in combination with fludarabine (Flu) and antithymocyte globulin (ATG) for MSD-PBSCT were investigated in 51 patients with acquired SAA. RESULTS: Overall survival and failure-free survival in patients received 150 mg/kg of Cy (Cy150 cohort) or 120 mg/kg (Cy120 cohort) were 93.5% vs 90.0% (χ(2)=0.170, P=0.680) and 90.3% vs 85.0% (χ(2)=0.285, P= 0.594) respectively. However, either acute or chronic graft-versus-host disease risks were higher in Cy120 cohort than in Cy150 cohort (HR=3.89, 95% CI 1.21–12.53, P=0.023; HR=4.48, 95% CI 1.40–14.32, P= 0.011, respectively). No difference was found for opportunistic infections or graft failure between two cohorts. CONCLUSION: Cy at a dose of 150 mg/kg, in combination with Flu and ATG, was more effective than that of 120 mg/kg Cy to produce improved clinical outcome in the setting of acquired SAA patients after MSD-PBSCT. Editorial office of Chinese Journal of Hematology 2017-08 /pmc/articles/PMC7348241/ /pubmed/28954343 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.08.003 Text en 2017年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal. |
spellingShingle | 论著 减低剂量环磷酰胺的预处理方案对重型再生障碍性贫血同胞全相合外周血造血干细胞移植疗效的影响 |
title | 减低剂量环磷酰胺的预处理方案对重型再生障碍性贫血同胞全相合外周血造血干细胞移植疗效的影响 |
title_full | 减低剂量环磷酰胺的预处理方案对重型再生障碍性贫血同胞全相合外周血造血干细胞移植疗效的影响 |
title_fullStr | 减低剂量环磷酰胺的预处理方案对重型再生障碍性贫血同胞全相合外周血造血干细胞移植疗效的影响 |
title_full_unstemmed | 减低剂量环磷酰胺的预处理方案对重型再生障碍性贫血同胞全相合外周血造血干细胞移植疗效的影响 |
title_short | 减低剂量环磷酰胺的预处理方案对重型再生障碍性贫血同胞全相合外周血造血干细胞移植疗效的影响 |
title_sort | 减低剂量环磷酰胺的预处理方案对重型再生障碍性贫血同胞全相合外周血造血干细胞移植疗效的影响 |
topic | 论著 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348241/ https://www.ncbi.nlm.nih.gov/pubmed/28954343 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.08.003 |
work_keys_str_mv | AT jiǎndījìliànghuánlínxiānàndeyùchùlǐfāngànduìzhòngxíngzàishēngzhàngàixìngpínxuètóngbāoquánxiānghéwàizhōuxuèzàoxuègànxìbāoyízhíliáoxiàodeyǐngxiǎng AT jiǎndījìliànghuánlínxiānàndeyùchùlǐfāngànduìzhòngxíngzàishēngzhàngàixìngpínxuètóngbāoquánxiānghéwàizhōuxuèzàoxuègànxìbāoyízhíliáoxiàodeyǐngxiǎng AT jiǎndījìliànghuánlínxiānàndeyùchùlǐfāngànduìzhòngxíngzàishēngzhàngàixìngpínxuètóngbāoquánxiānghéwàizhōuxuèzàoxuègànxìbāoyízhíliáoxiàodeyǐngxiǎng AT jiǎndījìliànghuánlínxiānàndeyùchùlǐfāngànduìzhòngxíngzàishēngzhàngàixìngpínxuètóngbāoquánxiānghéwàizhōuxuèzàoxuègànxìbāoyízhíliáoxiàodeyǐngxiǎng AT jiǎndījìliànghuánlínxiānàndeyùchùlǐfāngànduìzhòngxíngzàishēngzhàngàixìngpínxuètóngbāoquánxiānghéwàizhōuxuèzàoxuègànxìbāoyízhíliáoxiàodeyǐngxiǎng AT jiǎndījìliànghuánlínxiānàndeyùchùlǐfāngànduìzhòngxíngzàishēngzhàngàixìngpínxuètóngbāoquánxiānghéwàizhōuxuèzàoxuègànxìbāoyízhíliáoxiàodeyǐngxiǎng AT jiǎndījìliànghuánlínxiānàndeyùchùlǐfāngànduìzhòngxíngzàishēngzhàngàixìngpínxuètóngbāoquánxiānghéwàizhōuxuèzàoxuègànxìbāoyízhíliáoxiàodeyǐngxiǎng AT jiǎndījìliànghuánlínxiānàndeyùchùlǐfāngànduìzhòngxíngzàishēngzhàngàixìngpínxuètóngbāoquánxiānghéwàizhōuxuèzàoxuègànxìbāoyízhíliáoxiàodeyǐngxiǎng AT jiǎndījìliànghuánlínxiānàndeyùchùlǐfāngànduìzhòngxíngzàishēngzhàngàixìngpínxuètóngbāoquánxiānghéwàizhōuxuèzàoxuègànxìbāoyízhíliáoxiàodeyǐngxiǎng AT jiǎndījìliànghuánlínxiānàndeyùchùlǐfāngànduìzhòngxíngzàishēngzhàngàixìngpínxuètóngbāoquánxiānghéwàizhōuxuèzàoxuègànxìbāoyízhíliáoxiàodeyǐngxiǎng |